|会社名||Exelixis Inc （エクセリクス）|
|分野（sector）||Health Care ヘルスケア|
|産業（industry）||Biotechnology: Commercial Physical_Biological Resarch|
|業種||バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care）|
|概要||事業概要 エクセチクス（Exelixis Inc.）は癌の低分子療法の開発に取り組むバイオ企業。同社はcabozantinib（カボザンチニブ）（XL184）に資源を投入し、それの開発を集中する。同社は他の化合物製品も有する。カボザンチニブは臨床開発段階にあるMETの阻害剤で、複数の癌の適応症を包含する開発プログラムで査定される。カボザンチニブの臨床プログラムは転移性去勢抵抗性前立腺癌（CRPC）と甲状腺髄様癌の治療に集中し、他のタイプの腫瘍の査定も含む。カボザンチニブは腫瘍の増殖、血管侵入および/または転移のキードライバーであるタンパク質のMET、血管内皮増殖因子受容体２（VEGFR2）、及びトランスフェクション中の再構成（RET）を抑制する。 エクセリクスは米国のバイオ医薬品メ―カ―。主にがん治療のための小分子治療薬の開発、製品化に従事。進行性・転移性甲状腺髄様癌の治療薬「COMETRIO」(カボザンチニブ)に焦点を当てた臨床活動を行う。同社は1994年に設立され、カリフォルニア州サウスサンフランシスコに本社を置く。 Founded in 1994, Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, it established a broad drug discovery and development platform that has served as the foundation for its continued efforts to bring new cancer therapies to patients in need. Its discovery efforts have resulted in four commercially available products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO® (esaxerenone), and it has entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from its marketed products and collaborations, it is committed to prudently reinvesting in its business to maximize the potential of its pipeline. It is supplementing its existing therapeutic assets with targeted business development activities and internal drug discovery - all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of the Standard & Poor's (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies. In November 2020, the company was named to Fortune's 100 Fastest-Growing Companies list for the first time, ranking 17th overall and the third-highest biopharmaceutical company.|
|本社所在地||1851 Harbor Bay Parkway Alameda CA 94502 USA|
|代表者氏名||Stelios Papadopoulos Stelios Papadopoulos|
|代表者役職名||Independent Chairman of the Board Co-Founder|
|市場名||NASDAQ National Market System|
|決算概要||決算概要 BRIEF: For the 26 weeks ended 30 June 2018 Exelixis Inc. revenues increased from $179.9M to $398.5M. Net income increased from $34.4M to $203.4M. Revenues reflect Net product revenues increase of 79% to $280.1M Collaboration revenues increase from $23M to $118.3M. Net income benefited from Interest expense decrease from $8.7M (expense) to $0K Interest Income increase of 71% to $4.6M (income).|
The Daily Biotech Pulse: Lilly, Morphic''s Positive Data At ECCO, Humanigen''s COVID Treatment Gets Expedited Review In UK, TransCode IPO 2021/07/09 11:36:16 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO ) ( moved on positive analyst action) Ambrx Biopharma Inc. (NYSE: AMAM ) AtriCure, Inc. (NASDAQ: ATRC ) Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN ) BioLife Solutions, Inc. (NASDAQ: BLFS ) Edwards Lifesciences Corporation (NYSE: EW ) Novo Nordisk A/S (NYSE: NVO ) Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX ) West Pharmaceutical Services, Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows July 8) 89bio, Inc. (NASDAQ: ETNB ) AbCellera Biologics Inc. (NASDAQ: ABCL ) Achilles Therapeutics plc (NASDAQ: ACHL ) Adicet Bio, Inc. (NASDAQ: ACET ) ADMA Biologics, Inc. (NASDAQ: ADMA ) Aerovate Therapeutics, Inc. (NASDAQ: AVTE ) (IPOed June 30) Agile Therapeutics, Inc. (NASDAQ: AGRX ) Akero Therapeutics, Inc. (NASDAQ: AKRO ) (announced positive Phase 2 data for non-alcoholic steatohepatitis drug) Allogene Therapeutics, Inc.
Exelixis to Present at the Virtual William Blair Biotech Focus Conference on July 15, 2021 2021/07/08 20:05:00 Business Wire
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Peter Lamb, Ph.D., the companys Executive Vice President, Scientific Strategy and Chief Scientific Officer, will present at the virtual William Blair Biotech Focus Conference 2021 on Thursday, July 15th at 2:00 p.m. EDT / 1:00 p.m. CDT / 11:00 a.m. PDT. To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Pleas
Will Exelixis Inventory See Even Decrease Ranges After Unfavourable Information From A Scientific Trial? 2021/07/01 08:21:46 FXNews24
The inventory worth of Exelixis (NASDAQ: EXEL), a genomics-based prescribed drugs firm targeted on oncology remedies, has seen a giant 21% drop during the last 5 buying and selling days, after the corporate introduced a destructive consequence from its medical trials for Cabometyx in beforehand untreated liver most cancers sufferers. Whereas the mixture of Cabometyx and  The post Will Exelixis Inventory See Even Decrease Ranges After Unfavourable Information From A Scientific Trial? appeared first on UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News .
Biotech Stock Roundup: NTLA Surges on Study Data, EXEL & ALT Down on Updates & More 2021/06/30 21:34:20 FXNews24
It was a busy week for the volatile biotech sector with quite a few pipeline and regulatory updates. New drug approvals also continue to be in focus along with news related to vaccines for COVID-19. Recap of the Weeks Most Important Stories: Exelixis Down on Study Update: Shares of Exelixis, Inc. EXEL declined after it  The post Biotech Stock Roundup: NTLA Surges on Study Data, EXEL & ALT Down on Updates & More appeared first on UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News .
Whats Next for Exelixis Stock After Disappointing Advanced Liver Cancer Data 2021/06/30 21:33:07 TipRanks
Decent is not good enough in the biotech world, where a drug needs to meet an exacting standard in order to cut the mustard. Which is the story of the
Molson Coors Beverage Company Consensus Indicates Potential 2.2% Upside 2021/06/24 09:50:07 DirectorsTalk
Molson Coors Beverage Company found using ticker (TAP) have now 17 analysts in total covering the stock. The consensus rating is ''Hold''. The range between the high target price and low target price is between 64.37 and 32 calculating the mean target price we have 43.73. Given that the stocks previous close was at 42.8 this would imply there is a potential upside of 2.2%. The day 50 moving average is 35.66 and the 200 moving average now moves to 36.95. The company has a market capitalisation of $9,195m. Visit the company website at: /> [stock_market_widget type="chart" symbol="TAP" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Molson Coors Beverage Company manufactures, markets, and sells beer and other malt beverage products in the United States, Canada, Europe, and internationally. The company sells various products under the Blue Moon, Coors Banquet, Coors Light, Miller Genuine Draft, Miller Lite, Hamm''s, Icehouse, Keystone, Mickey''s, Miller64, Miller High Life, Milwaukee''s Best, Olde English, Steel Reserve, Hop Valley, Leinenkugel''s, Peroni Nastro Azurro, Pilsner Urquell, Revolver, Saint Archer, Sol, Terrapin, Crispin, Smith & Forge, Arnold Palmer Spiked, Cape Line, Henry''s Hard, Redd''s, and Steel Reserve Alloy Series brands.
Antenna Transducer and Radome Market Outlook to 2028 - COVID-19 Impact and Global Analysis By Cobham Limited, Exelixis, Inc., Leonardo S.p.A., L3Harris Technologies, Lockheed Martin Corporation 2021/06/23 11:59:27 Industry Today
Antenna Transducer and Radome Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Product (Antenna , Transducer, Radome); Platform (Ground, Naval, Airborne); Technology (Radar, Communication, Sonar) and Geography Posted via Industry Today. Follow us on Twitter @IndustryToday
Kidney Cancer Drugs Global Market Report 2021: COVID-19 Impact And Recovery To 2030 2021/06/22 09:43:00 Intrado Digital Media
Major players in the kidney cancer drugs market are Bayer AG, Pfizer Inc. , Novartis International AG, Exelixis, Inc. , and F. Hoffmann-La Roche Ag. The global kidney cancer drugs market is expected to decline from $3. Major players in the kidney cancer drugs market are Bayer AG, Pfizer Inc. , Novartis International AG, Exelixis, Inc. , and F. Hoffmann-La Roche Ag. The global kidney cancer drugs market is expected to decline from $3.
関連キーワード （バイオテクノロジ―_メディカルリサ―チ 米国株 エクセリクス EXEL Exelixis Inc.）